1. Home
  2. MODD vs VTGN Comparison

MODD vs VTGN Comparison

Compare MODD & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Modular Medical Inc.

MODD

Modular Medical Inc.

HOLD

Current Price

$2.03

Market Cap

28.5M

Sector

Health Care

ML Signal

HOLD

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

HOLD

Current Price

$0.29

Market Cap

25.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MODD
VTGN
Founded
1998
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.5M
25.3M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
MODD
VTGN
Price
$2.03
$0.29
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$0.90
AVG Volume (30 Days)
140.6K
2.6M
Earning Date
02-17-2026
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$124.49
Revenue Next Year
N/A
$353.99
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.12
$0.20
52 Week High
$6.16
$5.14

Technical Indicators

Market Signals
Indicator
MODD
VTGN
Relative Strength Index (RSI) 31.53 46.32
Support Level $0.31 $0.21
Resistance Level $5.76 $0.66
Average True Range (ATR) 0.34 0.02
MACD -0.04 0.02
Stochastic Oscillator 6.06 66.50

Price Performance

Historical Comparison
MODD
VTGN

About MODD Modular Medical Inc.

Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

Share on Social Networks: